Other Publications

  1. Maciewicz R and Mucke L (1987) Principles of pain management. In Current Therapy in Internal Medicine. Bayless TM, Brain MC, Cherniack RM (eds). B.C. Decker, Inc., pp. 1248–1253
  2. Maciewicz R and Mucke L (1987) Principles of pain management. In Current Therapy in Neurological Disease-2. Bayless TM, Brain MC, Cherniack RM (eds). B.C. Decker, Inc., pp. 43–48
  3. Benedek G, Mucke L, Norita M, Albowitz B, and Creutzfeldt OD (1988) Anterior ectosylvian visual area (AEV) of the cat: physiological properties. Prog. Brain. Res. 75: 245–255
  4. Abraham CR, Razzaboni BL, Papastoitsis G, Picard E, Kanemaru K, Meckelein B, and Mucke L (1992) Purification and cloning of brain proteases capable of degrading the b-amyloid precursor protein. Ann. N.Y. Acad. Sci. 674: 174–179
  5. Bloom FE, Campbell IL, and Mucke L (eds) (1993) Molecular and cellular mechanisms of neural-immune interactions. Discussions in Neuroscience, Vol. IX, Nos. 3+4. Elsevier Science Publishers, Amsterdam
  6. Masliah E, Ueda K, and Mucke L (1993) Pathophysiological basis of Alzheimer’s disease. In World Congress of Anatomic and Clinical Pathology. Santoscoy GG (ed). Moduzzi Editore, Bologna
  7. Mucke L (1993) Transgenic models to study diseases of the nervous system: an in vivo approach to dissect complex pathogenetic networks. In Symposium in Immunology II. Eibl MM, Huber C, Peter HH, Wahn U (eds). Springer-Verlag, Berlin, pp. 121–31
  8. Lipton SA, Brenneman DE, Silverstein FS, Masliah E, and Mucke L (1995) Gp120 and neurotoxicity in vivo. Trends Pharmacol. Sci. 16: 122
  9. Masliah E, Mallory M, Alford M, Ge N, and Mucke L (1995) Abnormal synaptic regeneration in hAPP695 transgenic and ApoE knockout mice. In Research Advances in Alzheimer's Disease and Related Disorders. Iqbal K, Mortimer J, Winblad B, Wisniewski H (eds). John Wiley & Sons, pp. 405–414
  10. Mucke L, Masliah E, and Campbell IL (1995) Transgenic models to assess the neuropathogenic potential of HIV-1 proteins and cytokines. Curr. Top. Microbiol. Immunol. 202: 187–205
  11. Mucke L, Abraham CR, and Masliah E (1996) Neurotrophic and neuroprotective effects of hAPP in transgenic mice. Ann. N.Y. Acad. Sci. 777: 82–89
  12. Masliah E, Ge N, and Mucke L (1996) Pathogenesis of HIV-1 associated neurodegeneration. Crit. Rev. Neurobiol. 10: 57–67
  13. Toggas SM and Mucke L (1996) Transgenic models in the study of AIDS dementia complex. Curr. Top. Microbiol. Immunol. 206: 223–241
  14. Mucke L and Buttini M (1998) Molecular basis of HIV-associated neurologic disease. In Molecular Neurology. Martin J (ed). Scientific American Medicine, New York, pp. 135–154
  15. Toggas SM and Mucke L (1998) Transgenic models to assess the pathogenic potential of viral products in HIV-1-associated CNS disease. In The Neurology of AIDS. Gendelman HE, Lipton S, Swindells S (eds). Chapman & Hall, New York. pp. 156–167
  16. Mucke L, Buttini M, Mahley RW, Pitas RE, Raber J, and Wyss-Coray T (2000) Contributions of the glial injury response to the multifactorial pathogenesis of Alzheimer’s disease. In Neuro-Immune Interactions in Neurologic Disorders. Patterson P, Kordon C, Christen Y (eds). Springer-Verlag, Berlin, pp. 19–33
  17. Wyss-Coray T, Lin C, Von Euw D, Masliah E, Mucke L, and Lacombe P (2000) Alzheimer’s disease-like cerebrovascular pathology in transforming growth factor-b1 transgenic mice and functional metabolic correlates. Ann. N.Y. Acad. Sci. 903: 317–323
  18. Wyss-Coray T and Mucke L (2000) Ibuprofen, inflammation and Alzheimer disease. Nat. Med. 6: 973–974
  19. Raber J, LeFevour A, and Mucke L (2001) Androgen treatment reduces cognitive deficits in female apoE4 transgenic mice. In Alzheimer’s Disease: Advances in Etiology, Pathogenesis and Therapeutics. Iqbal K, Sisodia S, Winblad B (eds), John Wiley & Sons, Ltd., pp. 747–757
  20. Huang Y, Weisgraber KH, Mucke L, and Mahley RW (2003) Apolipoprotein E: Diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer’s disease. J. Mol. Neurosci. 23: 189–204
  21. Mucke L and Pitas R (2004) Food for thought: Essential fatty acid protects against neuronal deficits in transgenic mouse model of AD. Neuron 43: 596–599
  22. Morris R and Mucke L (2006) Alzheimer's disease: A needle from the haystack. Nature 440: 284–285
  23. Chin J, Roberson ED, and Mucke L (2008) Molecular aspects of memory dysfunction in Alzheimer’s disease. Vol. 4, Chapter 15, pp. 245–293. In Learning and Memory:  A Comprehensive Reference. John Byrne (ed), Elsevier
  24. Cisse M and Mucke L (2009) Alzheimer’ disease: A prion protein connection. Nature 457: 1090–1091
  25. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ (2009) A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 5: 85–92
  26. Mucke L (2009) Alzheimer’s disease. Nature 461: 895–897
  27. Mucke L and Selkoe DJ (2012) Neurotoxicity of amyloid b-protein. Cold Spring Harb. Perspect. Med. 2: a006338
  28. Alzheimer’s Association Expert Advisory Workgroup on NAPA (2012) Workgroup on NAPA’s agenda for a national initiative on Alzheimer’s disease. Alzheimers Dement. 8: 357-371